CN108727229B - Novel process route for modifying fatty acid type PET reagent precursor - Google Patents

Novel process route for modifying fatty acid type PET reagent precursor Download PDF

Info

Publication number
CN108727229B
CN108727229B CN201710250117.9A CN201710250117A CN108727229B CN 108727229 B CN108727229 B CN 108727229B CN 201710250117 A CN201710250117 A CN 201710250117A CN 108727229 B CN108727229 B CN 108727229B
Authority
CN
China
Prior art keywords
compound
reaction
process according
carried out
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710250117.9A
Other languages
Chinese (zh)
Other versions
CN108727229A (en
Inventor
徐新盛
刘爽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Xiantong International Pharmaceutical Technology Co ltd
Original Assignee
Beijing Xiantong International Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Xiantong International Pharmaceutical Technology Co ltd filed Critical Beijing Xiantong International Pharmaceutical Technology Co ltd
Priority to CN201710250117.9A priority Critical patent/CN108727229B/en
Publication of CN108727229A publication Critical patent/CN108727229A/en
Application granted granted Critical
Publication of CN108727229B publication Critical patent/CN108727229B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/36Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal
    • C07C29/38Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal by reaction with aldehydes or ketones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01Preparation of ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/16Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/08Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/24Preparation of carboxylic acid esters by reacting carboxylic acids or derivatives thereof with a carbon-to-oxygen ether bond, e.g. acetal, tetrahydrofuran
    • C07C67/26Preparation of carboxylic acid esters by reacting carboxylic acids or derivatives thereof with a carbon-to-oxygen ether bond, e.g. acetal, tetrahydrofuran with an oxirane ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/30Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D301/00Preparation of oxiranes
    • C07D301/02Synthesis of the oxirane ring
    • C07D301/03Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds
    • C07D301/14Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with organic peracids, or salts, anhydrides or esters thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

The invention discloses a novel process route for synthesizing a modified long-chain fatty acid type PET reagent precursor. The route has the characteristics of easily obtained starting materials, simple route, mild reagents, high yield and the like.

Description

Novel process route for modifying fatty acid type PET reagent precursor
Technical Field
The invention belongs to the field of organic chemical synthesis, and particularly relates to a novel process route for modifying a fatty acid type PET reagent precursor.
Background
PET (positron emission tomography) is a relatively advanced clinical examination imaging technique in the field of nuclear medicine. The general method is to mix a certain substance, which is generally necessary in the metabolism of biological life, such as: glucose, proteins, nucleic acids, fatty acids, labelled with short-lived radionuclides (e.g. F)18,C11Etc.) to reflect the metabolic activity of the living body by the accumulation of the substance in metabolism after the injection into the human body, thereby achieving the purpose of diagnosis.
In the basal aerobic metabolism of the myocardium, 70% of ATP is produced by beta-oxidation of fatty acids, and thus fatty acids or modified fatty acids are suitable cardiac positron emission computed tomography reagents. Modified fatty acids have greater diagnostic value due to the fact that the rate of metabolism of unmodified fatty acids is too fast to concentrate more radioactive atoms in the liver or lung than the site of diagnostic interest. [18F]Cardiopet is an innovative PET agent and is currently undergoing clinical phase II research work. It is characterized in that in CH2CO2The cyclopropane ring is introduced at the H group, so that the absorption and enrichment behaviors of the cyclopropane ring are similar to those of fatty acid, but the cyclopropane ring is difficult to perform beta-oxidation, and therefore the cyclopropane ring can be retained in cardiac muscle cells and can be caused by18The decay of F produces positrons that form medically useful images for studying cardiac metabolism and disease diagnosis, particularly coronary heart disease.
The compounds of the formulae (I), (Ia) and (Ib) are [, [2]18F]Precursors of Cardiopet with isotopically irradiated generated K18F is subjected to substitution reaction and hydrolysis reaction, and then purified by semi-preparative chromatography for diagnostic use (reference: US7790142, US 2004253177).
Figure BDA0001271841710000011
Figure BDA0001271841710000021
The existing synthetic route of the compound shown in the formula (Ib) is as long as 20 steps, the yield is low, the production process is complex, and therefore, the cost is high, and the industrialization is difficult. And requires the use of a variety of highly toxic, explosive, environmentally unfriendly reagents such as potassium cyanide, diazomethane, pyridinium chlorochromate, and the like:
Figure BDA0001271841710000022
in summary, the compounds of formulae (I), (Ia) and (Ib) are precursors of modified fatty acid-based PET agents in the second phase of clinical studies. However, the materials used are not suitable for industrial production due to the long synthetic route. In order to realize industrialization at low cost and benefit heart disease patients, it is necessary to design and develop a new process route.
Disclosure of Invention
For improving18F]The precursor compounds of CardioPET, namely the compounds shown as the formula (I), (Ia) and (Ib), have the defects of long process route, low yield, unfriendly reagent industry and the like, the whole process route is redesigned and developed, so that the route is shortened from 20 steps to 11 steps, and the total yield is improved from 1% to more than 5%:
Figure BDA0001271841710000031
the synthesis method of the invention is adopted to synthesize18F]The precursor compound of CardioPET, namely the compound shown in formula (I), adopts a novel process route, has the yield of more than 5 percent, and has the characteristics of simple operation, low toxicity and risk of used reagents and the like.
Accordingly, in the technical scheme [1] of the present invention, there is provided a process for producing a compound of the formula (I),
Figure BDA0001271841710000032
wherein,r represents C1-6Alkyl radical, C1-6Haloalkyl, C2-6Alkenyl radical, C2-6Alkynyl, C3-7Cycloalkyl, 3-7 membered heterocyclyl, C6-10Aryl or 5-10 membered heteroaryl;
x is sulfonyl;
it was prepared using compound 7 as starting material:
Figure BDA0001271841710000033
wherein Pg represents a protecting group.
In a particular embodiment of this embodiment, R is selected from methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, isopentyl, cyclopropyl, cyclopentyl, or the like; in a particular embodiment of this embodiment, R is tert-butyl.
In a particular embodiment of this embodiment, X is selected from methylsulfonyl, p-toluenesulfonyl, trifluoromethanesulfonyl, and the like; in a particular embodiment of this embodiment, X is methanesulfonyl.
In a particular embodiment of this embodiment, Pg is preferably a protecting group selected from benzyl, 4-methylbenzyl, 4-methoxybenzyl, tert-butyldimethylsilyl, triisopropylsilyl, triethylsilyl; in a particular embodiment of this aspect, Pg is preferably benzyl.
In technical scheme [2] of the present invention, there is provided a method according to technical scheme [1], which comprises a step of oxidizing compound 7 to compound 8:
Figure BDA0001271841710000041
in a particular embodiment of this aspect, wherein the oxidation reaction is preferably carried out using an oxidizing agent selected from the group consisting of: sodium chlorite, potassium permanganate, PCC or manganese dioxide.
In technical scheme [3] of the present invention, there is provided the process according to technical scheme [1] or [2], further comprising the step of esterifying compound 8 to obtain compound 9:
Figure BDA0001271841710000042
in technical scheme [4] of the present invention, there is provided the method according to any one of technical schemes [1] to [3], further comprising a step of deprotecting the compound 9 to obtain a compound 10:
Figure BDA0001271841710000043
in technical scheme [5] of the present invention, there is provided a process according to any one of technical schemes [1] to [4], further comprising a step of sulfonylating compound 10 to obtain a compound of formula (I):
Figure BDA0001271841710000051
in technical scheme [6] of the present invention, there is provided a process according to any one of technical schemes [1] to [5], further comprising a step of converting compound 6 into compound 7:
Figure BDA0001271841710000052
in a particular embodiment of this embodiment, the hydrolysis reaction is preferably carried out under acidic conditions; in a particular embodiment of this embodiment, the hydrolysis reaction is preferably carried out using an acid selected from the group consisting of: hydrochloric acid, perchloric acid, sulfuric acid, methanesulfonic acid, trifluoromethanesulfonic acid, or trifluoroacetic acid.
In technical scheme [7] of the present invention, there is provided the method according to any one of technical schemes [1] to [6], further comprising a step of subjecting compound 5 to Wittig reaction to thereby obtain compound 6:
Figure BDA0001271841710000053
in a particular embodiment of this embodiment, wherein said Wittig reaction is preferably carried out in the presence of an organic base; in a particular embodiment of this embodiment, the organic base is preferably selected from sodium hydride, LDA, potassium tert-butoxide, butyllithium, LiHMDS, NaHMDS, KHMDS or sodium amide; in a particular embodiment of this embodiment, the organic base is preferably sodium hydride.
In technical scheme [8] of the present invention, there is provided the method according to any one of technical schemes [1] to [7], further comprising the step of reducing compound 4 to give compound 5:
Figure BDA0001271841710000054
in a specific embodiment of this embodiment, the reduction reaction selectively reduces the ester to an aldehyde; in a specific embodiment of this embodiment, the selective reduction is performed using DIBAL-H.
In a specific embodiment of this embodiment, the reduction reaction comprises a two-step reaction of first reducing the ester completely to an alcohol and then oxidizing the alcohol to an aldehyde; in a particular embodiment of this embodiment, the two-step reaction comprises: the first reaction step uses NaBH4Borane-tetrahydrofuran complex, lithium aluminum hydride, DIBAL-H, red aluminum, etc., and the second reaction is carried out using activated manganese dioxide, PCC or dessamidine reagent.
In technical scheme [9] of the present invention, there is provided the method according to any one of technical schemes [1] to [8], further comprising a step of subjecting compound 3 to Wadsworth Emmons cyclopropanation to give compound 4:
Figure BDA0001271841710000061
in a particular embodiment of this embodiment, said Wadsworth Emmons cyclopropanation is preferably carried out in the presence of an organic base; in a particular embodiment of this embodiment, the organic base is selected from sodium hydride, LDA, potassium tert-butoxide, butyllithium, LiHMDS, NaHMDS, KHMDS, or sodium amide; in a specific embodiment of this embodiment, the organic base is sodium hydride.
In technical scheme [10] of the present invention, there is provided the process according to any one of technical schemes [1] to [9], further comprising a step of epoxidizing a double bond in compound 2 to give compound 3:
Figure BDA0001271841710000062
in a particular embodiment of this embodiment, the epoxidation is preferably carried out using an agent selected from the group consisting of: mCPBA, hydrogen peroxide, peracetic acid, t-butanol peroxide, or cumene peroxide; in a particular embodiment of this embodiment, the epoxidation is preferably carried out using mCPBA.
In technical scheme [11] of the present invention, there is provided the method according to any one of technical schemes [1] to [10], further comprising a step of protecting a hydroxyl group of compound 1 with a protecting group Pg to obtain compound 2:
Figure BDA0001271841710000063
in technical solution [12] of the present invention, there is provided the method according to any one of technical solutions [1] to [11], further comprising the step of subjecting the starting materials aldehyde and halide to a nucleophilic addition reaction of a metal organic reagent and aldehyde to obtain compound 1:
Figure BDA0001271841710000071
wherein R is1Is an aldehyde group, R2Is halogen; or R1Is halogen, R2Is an aldehyde group.
In a particular embodiment of this embodiment, the halogen is preferably Cl or Br; in a specific embodiment of this embodiment, the reaction is preferably carried out in an organic solvent such as tetrahydrofuran, 2-methyltetrahydrofuran or diethyl ether, with magnesium, indium, zinc or lithium as the metal; in a particular embodiment of this embodiment, the reaction is preferably carried out with magnesium as metal in tetrahydrofuran.
In technical solution [13] of the present invention, there is provided the method according to any one of technical solutions [1] to [12], which comprises the steps of:
Figure BDA0001271841710000072
in technical solution [14] of the present invention, there is provided the method according to any one of technical solutions [1] to [13], which comprises the steps of:
Figure BDA0001271841710000081
in technical solution [15] of the present invention, there is provided the method according to any one of technical solutions [1] to [14], comprising the steps of:
Figure BDA0001271841710000082
in technical scheme [16] of the present invention, there is provided compound 7:
Figure BDA0001271841710000083
wherein Pg represents a protecting group.
In a particular embodiment of this embodiment, Pg is preferably a protecting group selected from benzyl, 4-methylbenzyl, 4-methoxybenzyl, tert-butyldimethylsilyl, triisopropylsilyl, triethylsilyl; in a particular embodiment of this aspect, Pg is preferably benzyl.
In technical scheme [17] of the present invention, there is provided the use of compound 7 in the preparation of a compound of formula (I).
Detailed Description
Definition of
All terms used herein have the meanings commonly understood by those skilled in the art. Further, the following meanings may be also possible.
“C1-6Alkyl "means a straight or branched chain saturated monovalent alk (en) yl group containing 1 to 6 carbon atoms. In some embodiments, C1-4Alkyl groups are preferred. Typical C1-6Alkyl includes methyl (C)1) Ethyl (C)2) N-propyl (C)3) Isopropyl (C)3) N-butyl (C)4) Tert-butyl (C)4) Sec-butyl (C)4) Isobutyl (C)4) N-pentyl group (C)5) 3-pentyl radical (C)5) Isopentyl group (C)5) Neopentyl (C)5) 3-methyl-2-butyl (C)5) Tert-amyl (C)5) And n-hexyl (C)6) And the like. The term "C1-6Alkyl "also includes heteroalkyl wherein from 1 to 3 nitrogen atoms selected from O, S, N or substituted may be substituted for carbon atoms.
“C2-6Alkenyl "represents a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon double bond, including but not limited to vinyl, 3-buten-1-yl, 2-vinylbutyl, 3-hexen-1-yl, and the like. In some embodiments, C2-4Alkenyl groups are preferred. The term "C2-6Alkenyl "also includes heteroalkenyl, wherein from 1 to 3 nitrogen atoms selected from O, S, N or substituted may be substituted for carbon atoms.
“C2-6Alkynyl "refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms containing at least one carbon-carbon triple bond and optionally one or more unsaturated carbon-carbon double bonds. In some embodiments, C2-4Alkynyl groups are preferred. Typical alkynyl groups include ethynyl, propynyl, isopropynyl, butynyl, isobutynyl, pentynyl, and hexynyl. The term "C2-6Alkynyl also includes heteroalkynyl wherein from 1 to 3 nitrogen atoms selected from O, S, N or substituted may be substituted for a carbon atom.
The term "halogen" as used herein refers to F, Cl, Br and I. Preferably, the halogen in the present invention is selected from Cl, Br and I; more preferably, the halogen in the present invention is selected from Cl or Br.
“C1-6Haloalkyl "means" C "as defined above1-6Alkyl ", which is substituted with one or more halogens. In some embodiments, C1-4Haloalkyl is preferred, more preferably C1-2A haloalkyl group. Exemplary said haloalkyl groups include, but are not limited to: -CF3、-CH2F、-CHF2、-CHFCH2F、-CH2CHF2、-CF2CF3、-CCl3、-CH2Cl、-CHCl22,2, 2-trifluoro-1, 1-dimethyl-ethyl, and the like.
“C3-7Cycloalkyl "refers to a non-aromatic cyclic hydrocarbon group having 3 to 7 ring carbon atoms and zero heteroatoms. In some embodiments, C3-6Cycloalkyl is particularly preferred, more preferably C5-6A cycloalkyl group. Cycloalkyl also includes ring systems in which the aforementioned cycloalkyl ring is fused to one or more aryl or heteroaryl groups, where the point of attachment is on the cycloalkyl ring, and in such cases the number of carbons continues to represent the number of carbons in the cycloalkyl system. Exemplary such cycloalkyl groups include, but are not limited to: cyclopropyl (C)3) Cyclopropenyl group (C)3) Cyclobutyl (C)4) Cyclobutenyl radical (C)4) Cyclopentyl (C)5) Cyclopentenyl group (C)5) Cyclohexyl (C)6) Cyclohexenyl (C)6) Cyclohexyldienyl (C)6) Cycloheptyl (C)7) Cycloheptenyl (C)7) Cycloheptadienyl (C)7) Cycloheptatrienyl (C)7) And so on.
"3-7 membered heterocyclyl" means a 3 to 7 membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms; preferably a 3-6 membered heterocyclic group which is a 3 to 6 membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; preferably a 4-6 membered heterocyclic group which is a 4 to 6 membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms; more preferably a 5-6 membered heterocyclic group having ring carbon atoms and 1 to 3 ringsA 5 to 6 membered non aromatic ring system of heteroatoms. Heterocyclyl also includes ring systems wherein the aforementioned heterocyclyl ring is fused to one or more cycloalkyl groups, wherein the point of attachment is on the cycloalkyl ring, or ring systems wherein the aforementioned heterocyclyl ring is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring; and in such cases the number of ring members continues to represent the number of ring members in the heterocyclyl ring system. Exemplary 3-membered heterocyclic groups containing one heteroatom include, but are not limited to: aziridinyl, oxacyclopropaneyl, thienylyl. Exemplary 4-membered heterocyclic groups containing one heteroatom include, but are not limited to: azetidinyl, oxetanyl and thietanyl. Exemplary 5-membered heterocyclic groups containing one heteroatom include, but are not limited to: tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2, 5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to: dioxolanyl, oxathiolanyl (oxathiolanyl), dithiolanyl (disulphuryl), and oxazolidin-2-one. Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to: triazolinyl, oxadiazolinyl and thiadiazolinyl. Exemplary 6-membered heterocyclic groups containing one heteroatom include, but are not limited to: piperidinyl, tetrahydropyranyl, dihydropyridinyl and thiacyclohexyl (thianyl). Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to: piperazinyl, morpholinyl, dithiinyl, dioxanyl. Exemplary 6-membered heterocyclic groups containing three heteroatoms include, but are not limited to: hexahydrotriazinyl (triazinanyl). Exemplary 7-membered heterocyclic groups containing one heteroatom include, but are not limited to: azepane, oxepanyl and thiepane. Exemplary with C6Aryl ring fused 5-membered heterocyclyl (also referred to herein as 5, 6-bicyclic heterocyclyl) includes, but is not limited to: indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolonyl, and the like. Exemplary with C6Aryl ring fused 6-membered heterocyclyl (also referred to herein as 6, 6-bicyclic heterocyclyl) includes, but is not limited to: fourthlyHydroquinolinyl, tetrahydroisoquinolinyl, and the like.
“C6-10Aryl "refers to a group having a monocyclic or polycyclic (e.g., bicyclic) 4n +2 aromatic ring system (e.g., having 6 or 10 pi electrons shared in a cyclic arrangement) of 6 to 10 ring carbon atoms and zero heteroatoms. In some embodiments, an aryl group has six ring carbon atoms ("C)6Aryl "; for example, phenyl). In some embodiments, an aryl group has ten ring carbon atoms ("C)10Aryl "; e.g., naphthyl, e.g., 1-naphthyl and 2-naphthyl). Aryl also includes ring systems in which the aforementioned aryl ring is fused to one or more cycloalkyl or heterocyclyl groups, and the point of attachment is on the aryl ring, in which case the number of carbon atoms continues to represent the number of carbon atoms in the aryl ring system.
"5-10 membered heteroaryl" refers to a group having a 5-10 membered monocyclic or bicyclic 4n +2 aromatic ring system (e.g., having 6 or 10 pi electrons shared in a cyclic arrangement) with ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur. In heteroaryl groups containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom, as valency permits. Heteroaryl bicyclic ring systems may include one or more heteroatoms in one or both rings. Heteroaryl also includes ring systems in which the aforementioned heteroaryl ring is fused to one or more cycloalkyl or heterocyclyl groups, and the point of attachment is on the heteroaryl ring, in which case the number of carbon atoms continues to represent the number of carbon atoms in the heteroaryl ring system. In some embodiments, 5-6 membered heteroaryl groups are particularly preferred, which are 5-6 membered monocyclic or bicyclic 4n +2 aromatic ring systems having ring carbon atoms and 1-4 ring heteroatoms. Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to: pyrrolyl, furanyl and thienyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to: imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to: triazolyl, oxadiazolyl and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to: a tetrazolyl group. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to: a pyridyl group. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to: pyridazinyl, pyrimidinyl and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to: triazinyl and tetrazinyl. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to: azepinyl, oxacycloheptyl, and thiacycloheptyl trienyl groups. Exemplary 5, 6-bicyclic heteroaryls include, but are not limited to: indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothienyl, isobenzothienyl, benzofuranyl, benzisothiafuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzooxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indezinyl, and purinyl. Exemplary 6, 6-bicyclic heteroaryls include, but are not limited to: naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl and quinazolinyl.
"Sulfonyl" denotes the group R-SO2-, wherein R represents C1-6Alkyl radical, C1-6Haloalkyl, C2-6Alkenyl radical, C2-6Alkynyl, C3-7Cycloalkyl, 3-7 membered heterocyclyl, C6-10Aryl or 5-10 membered heteroaryl.
"Methanesulfonyl" means the group Me-SO2-。
"P-toluenesulfonyl" denotes the group p-CH3-C6H4-SO2-。
"Trifluoromethanesulfonyl" denotes the group CF3-SO2-。
Alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, and the like, as defined herein, are optionally substituted groups.
Exemplary substituents on carbon atoms include, but are not limited to: halogen, -CN, -NO2、-N3、-SO2H、-SO3H、-OH、-ORaa、-ON(Rbb)2、-N(Rbb)2、-N(Rbb)3 +X-、-N(ORcc)Rbb、-SH、-SRaa、-SSRcc、-C(=O)Raa、-CO2H、-CHO、-C(ORcc)2、-CO2Raa、-OC(=O)Raa、-OCO2Raa、-C(=O)N(Rbb)2、-OC(=O)N(Rbb)2、-NRbbC(=O)Raa、-NRbbCO2Raa、-NRbbC(=O)N(Rbb)2、-C(=NRbb)Raa、-C(=NRbb)ORaa、-OC(=NRbb)Raa、-OC(=NRbb)ORaa、-C(=NRbb)N(Rbb)2、-OC(=NRbb)N(Rbb)2、-NRbbC(=NRbb)N(Rbb)2、-C(=O)NRbbSO2Raa、-NRbbSO2Raa、-SO2N(Rbb)2、-SO2Raa、-SO2ORaa、-OSO2Raa、-S(=O)Raa、-OS(=O)Raa、-Si(Raa)3、-OSi(Raa)3、-C(=S)N(Rbb)2、-C(=O)SRaa、-C(=S)SRaa、-SC(=S)SRaa、-SC(=O)SRaa、-OC(=O)SRaa、-SC(=O)ORaa、-SC(=O)Raa、-P(=O)2Raa、-OP(=O)2Raa、-P(=O)(Raa)2、-OP(=O)(Raa)2、-OP(=O)(ORcc)2、-P(=O)2N(Rbb)2、-OP(=O)2N(Rbb)2、-P(=O)(NRbb)2、-OP(=O)(NRbb)2、-NRbbP(=O)(ORcc)2、-NRbbP(=O)(NRbb)2、-P(Rcc)2、-P(Rcc)3、-OP(Rcc)2、-OP(Rcc)3、-B(Raa)2、-B(ORcc)2、-BRaa(ORcc) Alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted with 0, 1, 2,3, 4 or 5RddSubstituted by groups;
or two geminal hydrogens on a carbon atom are replaced by groups ═ O, ═ S, ═ NN (R)bb)2、=NNRbbC(=O)Raa、=NNRbbC(=O)ORaa、=NNRbbS(=O)2Raa、=NRbbOr as NORccSubstitution;
Raaeach is independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two RaaThe groups combine to form a heterocyclyl or heteroaryl ring wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2,3, 4, or 5RddSubstituted by groups;
Rbbeach independently selected from: hydrogen, -OH, -ORaa、-N(Rcc)2、-CN、-C(=O)Raa、-C(=O)N(Rcc)2、-CO2Raa、-SO2Raa、-C(=NRcc)ORaa、-C(=NRcc)N(Rcc)2、-SO2N(Rcc)2、-SO2Rcc、-SO2ORcc、-SORaa、-C(=S)N(Rcc)2、-C(=O)SRcc、-C(=S)SRcc、-P(=O)2Raa、-P(=O)(Raa)2、-P(=O)2N(Rcc)2、-P(=O)(NRcc)2Alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two RbbThe groups combine to form a heterocyclyl or heteroaryl ring wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, arylAnd heteroaryl is independently substituted with 0, 1, 2,3, 4 or 5RddSubstituted by groups;
Rcceach is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or two RccThe groups combine to form a heterocyclyl or heteroaryl ring wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2,3, 4, or 5RddSubstituted by groups;
Rddeach independently selected from: halogen, -CN, -NO2、-N3、-SO2H、-SO3H、-OH、-ORee、-ON(Rff)2、-N(Rff)2、-N(Rff)3 +X-、-N(ORee)Rff、-SH、-SRee、-SSRee、-C(=O)Ree、-CO2H、-CO2Ree、-OC(=O)Ree、-OCO2Ree、-C(=O)N(Rff)2、-OC(=O)N(Rff)2、-NRffC(=O)Ree、-NRffCO2Ree、-NRffC(=O)N(Rff)2、-C(=NRff)ORee、-OC(=NRff)Ree、-OC(=NRff)ORee、-C(=NRff)N(Rff)2、-OC(=NRff)N(Rff)2、-NRffC(=NRff)N(Rff)2、-NRffSO2Ree、-SO2N(Rff)2、-SO2Ree、-SO2ORee、-OSO2Ree、-S(=O)Ree、-Si(Ree)3、-OSi(Ree)3、-C(=S)N(Rff)2、-C(=O)SRee、-C(=S)SRee、-SC(=S)SRee、-P(=O)2Ree、-P(=O)(Ree)2、-OP(=O)(Ree)2、-OP(=O)(ORee)2Alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is independently substituted with 0, 1, 2,3, 4 or 5RggSubstituted by radicals, or two geminal RddSubstituents may combine to form ═ O or ═ S;
Reeis independently selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2,3, 4, or 5RggSubstituted by groups;
Rffeach is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or two RffThe groups combine to form a heterocyclyl or heteroaryl ring wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2,3, 4, or 5RggSubstituted by groups;
Rggis independently from each other: halogen, -CN, -NO2、-N3、-SO2H、-SO3H、-OH、-OC1-6Alkyl, -ON (C)1-6Alkyl radical)2、-N(C1-6Alkyl radical)2、-N(C1-6Alkyl radical)3 +X-、-NH(C1-6Alkyl radical)2 +X-、-NH2(C1-6Alkyl radical)+X-、-NH3 +X-、-N(OC1-6Alkyl) (C1-6Alkyl), -N (OH) (C)1-6Alkyl), -NH (OH), -SH, -SC1-6Alkyl, -SS (C)1-6Alkyl), -C (═ O) (C)1-6Alkyl), -CO2H、-CO2(C1-6Alkyl), -OC (═ O) (C)1-6Alkyl), -OCO2(C1-6Alkyl), -C (═ O) NH2、-C(=O)N(C1-6Alkyl radical)2、-OC(=O)NH(C1-6Alkyl), -NHC (═ O) (C)1-6Alkyl), -N (C)1-6Alkyl radical)C(=O)(C1-6Alkyl), -NHCO2(C1-6Alkyl), -NHC (═ O) N (C)1-6Alkyl radical)2、-NHC(=O)NH(C1-6Alkyl), -NHC (═ O) NH2、-C(=NH)O(C1-6Alkyl), -OC (═ NH) (C)1-6Alkyl), -OC (═ NH) OC1-6Alkyl, -C (═ NH) N (C)1-6Alkyl radical)2、-C(=NH)NH(C1-6Alkyl), -C (═ NH) NH2、-OC(=NH)N(C1-6Alkyl radical)2、-OC(NH)NH(C1-6Alkyl), -OC (NH) NH2、-NHC(NH)N(C1-6Alkyl radical)2、-NHC(=NH)NH2、-NHSO2(C1-6Alkyl), -SO2N(C1-6Alkyl radical)2、-SO2NH(C1-6Alkyl), -SO2NH2、-SO2C1-6Alkyl, -SO2OC1-6Alkyl, -OSO2C1-6Alkyl, -SOC1-6Alkyl, -Si (C)1-6Alkyl radical)3、-OSi(C1-6Alkyl radical)3、-C(=S)N(C1-6Alkyl radical)2、C(=S)NH(C1-6Alkyl), C (═ S) NH2、-C(=O)S(C1-6Alkyl), -C (═ S) SC1-6Alkyl, -SC (═ S) SC1-6Alkyl, -P (═ O)2(C1-6Alkyl), -P (═ O) (C)1-6Alkyl radical)2、-OP(=O)(C1-6Alkyl radical)2、-OP(=O)(OC1-6Alkyl radical)2、C1-6Alkyl radical, C1-6Haloalkyl, C2-C6Alkenyl radical, C2-C6Alkynyl, C3-C7Cycloalkyl radical, C6-C10Aryl radical, C3-C7Heterocyclic group, C5-C10A heteroaryl group; or two geminal RggSubstituents may combine to form ═ O or ═ S; wherein, X-Are counter ions.
Exemplary substituents on the nitrogen atom include, but are not limited to: hydrogen, -OH, -ORaa、-N(Rcc)2、-CN、-C(=O)Raa、-C(=O)N(Rcc)2、-CO2Raa、-SO2Raa、-C(=NRbb)Raa、-C(=NRcc)ORaa、-C(=NRcc)N(Rcc)2、-SO2N(Rcc)2、-SO2Rcc、-SO2ORcc、-SORaa、-C(=S)N(Rcc)2、-C(=O)SRcc、-C(=S)SRcc、-P(=O)2Raa、-P(=O)(Raa)2、-P(=O)2N(Rcc)2、-P(=O)(NRcc)2Alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl, or two R's attached to a nitrogen atomccThe groups combine to form a heterocyclyl or heteroaryl ring wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2,3, 4, or 5RddIs substituted by radicals, and wherein Raa、Rbb、RccAnd RddAs described above.
The term "oxidation" as used herein refers to a reaction of introducing oxygen or removing hydrogen in the compound of the present invention. More specifically, it refers to a reaction that converts an aldehyde group to a carboxylic acid group. The oxidation reaction can be accomplished using a variety of oxidizing agents well known in the art, including but not limited to sodium chlorite, potassium permanganate, PCC, and manganese dioxide.
The term "reduction" as used herein refers to a reaction of introducing hydrogen or removing oxygen in the compound of the present invention. More specifically, it refers to a reaction of converting an ester group into an aldehyde group. The reduction may be accomplished using a variety of reducing agents well known in the art, including, but not limited to, one-step conversion of DIBAL-H, and first with NaBH4Borane-tetrahydrofuran complex, lithium aluminum hydride, DIBAL-H, red aluminum, etc., followed by two-step conversion with activated manganese dioxide, PCC or dessimutane reagent.
The term "protecting group" as used herein refers to a group that is capable of covalently bonding to a functional group, protecting it from chemical reactions, and being removed after the reaction is complete to recover the functional group. More specifically, the protecting group in the present invention refers to an oxygen protecting group (also referred to as a hydroxyl protecting group). Oxygen Protecting Groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, t.w.greene and p.g.m.wuts, third edition, John Wiley & Sons, 1999, which is incorporated herein by reference.
Exemplary oxygen protecting groups include, but are not limited to, methyl, t-butyloxycarbonyl (BOC or Boc), methoxymethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl) methoxymethyl (SMOM), Benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy) methyl (p-AOM), Guaiacolmethyl (GUM), t-butoxymethyl, 4-Pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2, 2-trichloroethoxymethyl, bis (2-chloroethoxy) methyl, 2- (trimethylsilyl) ethoxymethyl (SEMOR), Tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl group, 4-methoxytetrahydropyranyl group (MTHP), 4-methoxytetrahydrothiopyranyl group, 4-methoxytetrahydrothiopyranyl S, S-dioxide, 1- [ (2-chloro-4-methyl) phenyl group]-4-methoxypiperidin-4-yl (CTMP), 1, 4-bis
Figure BDA0001271841710000151
Alk-2-yl, tetrahydrofuryl, tetrahydrothienyl, 2,3,3a,4,5,6,7,7 a-octahydro-7, 8, 8-trimethyl-4, 7-methanobenzofuran (methanobenzofuran) -2-yl, 1-ethoxyethyl, 1- (2-chloroethoxy) ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2, 2-trichloroethyl, 2-trimethylsilylethyl, 2- (phenylhydrogenselenyl) ethyl, tert-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2, 4-dinitrophenyl, benzyl (Bn), P-methoxybenzyl, 3, 4-dimethoxybenzyl, o-nitrobenzyl, p-halobenzyl, 2, 6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxide, diphenylmethyl, p' -dinitrobenzhydryl, 5-dibenzosuberenyl, triphenylmethyl, alpha-naphthyldiphenylmethyl, p-methoxyphenylDiphenylmethyl, di (p-methoxyphenyl) phenylmethyl, tri (p-methoxyphenyl) methyl, 4- (4 '-bromobenzoyloxyphenyl) diphenylmethyl, 4', 4 "-tris (4, 5-dichlorophthalimidophenyl) methyl, 4 ', 4" -tris (levulinoyloxyphenyl) methyl, 4', 4 "-tris (benzoyloxyphenyl) methyl, 3- (imidazol-1-yl) bis (4 ', 4" -dimethoxyphenyl) methyl, 1-bis (4-methoxyphenyl) -1' -pyrenylmethyl, 9-anthracenyl, 9- (9-phenyl)
Figure BDA0001271841710000161
Xanthyl, 9- (9-phenyl-10-oxo) anthracenyl, 1, 3-benzodithiolan-2-yl, benzisothiazolyl S, S-dioxide, Trimethylsilyl (TMS), Triethylsilyl (TES), Triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), Diethylisopropylsilyl (DEIPS), dimethylhexylsilyl, tert-butyldimethylsilyl (TBDMS), tert-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, Diphenylmethylsilyl (DPMS), tert-butylmethoxyphenylsilyl (MPS), formate, benzoylformate, TBacetate, chloroacetate, dichloroacetate, trichloroacetate, Trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-pentanoate (levulinate), 4- (ethylenedithio) valerate (levulinyl dithioacetal), pivalate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4, 6-trimethylbenzoate (miketonate), alkyl methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2, 2-trichloroethyl carbonate (Troc), 2- (trimethylsilyl) ethyl carbonate (TMSEC), 2- (phenylsulfonyl) ethyl carbonate (Psec), 2- (triphenylphosphine.
Figure BDA0001271841710000162
Yl) Ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl EtherAlkenyl carbonate, alkylallyl carbonate, alkyl p-nitrophenyl carbonate, alkylbenzyl carbonate, alkyl p-methoxybenzyl carbonate, alkyl 3, 4-dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl S-benzylthiocarbonate, 4-ethoxy-1-naphthyl carbonate, methyldithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o- (dibromomethyl) benzoate, 2-formylbenzenesulfonate, 2- (methylthiomethoxy) ethyl, 4- (methylthiomethoxy) butyrate, 2- (methylthiomethoxymethyl) benzoate, 2, 6-dichloro-4-methylphenoxyacetate, alkyl p-nitrobenzyl carbonate, alkyl p-methoxybenzyl carbonate, alkyl 3, 4-dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl S-benzylthiocarbonate, 4-, 2, 6-dichloro-4- (1,1,3, 3-tetramethylbutyl) phenoxyacetate, 2, 4-bis (1, 1-dimethylpropyl) phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinate, (E) -2-methyl-2-butenoate, o- (methoxyacyl) benzoate, α -naphthoate, nitrate, alkyl N, N' -tetramethylphosphorodiamidite, alkyl N-phenylcarbamate, borate, dimethylphosphinylsulfinyl, alkyl 2, 4-dinitrophenylsulfenate, sulfate, methanesulfonate (methanesulfonate), benzylsulfonate, and tosylate (Ts).
"hydroxy protection" and "deprotection" refer to the reaction of introducing a protecting group to a hydroxy functional group and removing the protecting group to recover the hydroxy functional group, respectively. The reaction conditions for introducing and removing protecting groups are well known to those skilled in the art.
The term "esterification" as used in the present invention refers to a reaction of converting a carboxyl group into an ester group. The esterification reaction may be accomplished using a variety of reagents well known in the art, including but not limited to halogenated hydrocarbons, alcohols, and the like.
The term "sulfonylation" as used herein refers to a reaction that converts a hydroxyl group to a sulfonyloxy group. For example, methanesulfonyl chloride, methanesulfonic anhydride, p-toluenesulfonyl chloride, trifluoromethanesulfonic anhydride, and the like may effect the reaction.
The term "hydrolysis" as used herein refers to a reaction that deprotects a protected aldehyde group. For example, the reaction is carried out under acidic conditions, wherein the acid used includes, but is not limited to, hydrochloric acid, perchloric acid, sulfuric acid, methanesulfonic acid, trifluoromethanesulfonic acid, or trifluoroacetic acid.
The term "Wittig reaction" as used in the present invention refers to a reaction in which a carbonyl group is converted to an olefin with a phosphorus ylide. The conditions under which the Wittig reaction is carried out are well known to those skilled in the art and are preferably carried out in the presence of an organic base. The organic bases include, but are not limited to, sodium hydride, LDA, potassium tert-butoxide, butyllithium, LiHMDS, NaHMDS, KHMDS, and sodium amide.
The term "Wadsworth-Emmons reaction" as used in the present invention refers to a reaction in which ethylene oxide is converted to cyclopropane carboxylic acid ester using phosphorous phosphite ylide. The conditions under which the Wadsworth-Emmons reaction is carried out are well known to the person skilled in the art and are preferably carried out in the presence of an organic base. The organic bases include, but are not limited to, sodium hydride, LDA, potassium tert-butoxide, butyllithium, LiHMDS, NaHMDS, KHMDS, and sodium amide.
The term "nucleophilic addition reaction" as used herein refers to a reaction in which an alkyl halide reacts with a metal to form a metal organic compound, which is then reacted with an aldehyde ketone to form an alcohol. The conditions for carrying out the nucleophilic addition reaction of the metalorganic reagent and the aldehyde are well known to those skilled in the art. Preferably, the grignard reaction of the present invention is carried out in an organic solvent such as tetrahydrofuran, 2-methyltetrahydrofuran or diethyl ether with magnesium, indium, zinc or lithium as a metal.
The term "aldehyde group" as used herein refers to the group-C (O) H.
The term "epoxidation" as used in the present invention refers to the reaction of an olefinic bond to ethylene oxide. The conditions under which the epoxidation reaction is carried out are well known to those skilled in the art. Preferably, the epoxidation according to the invention is carried out using an agent selected from the group consisting of: mCPBA, hydrogen peroxide, peracetic acid, t-butanol peroxide, or cumene hydroperoxide.
Example 1
Reaction type
Figure BDA0001271841710000181
1. Synthesis of Compound 1
Adding magnesium chips and a little iodine into a 1L three-mouth bottle, and replacing and protecting by nitrogen. Then 60 ml of anhydrous THF and a small amount of 6-bromo-1-hexene were added and the temperature was raised to initiate the reaction. After initiation, 162 g of 6-bromo-1-hexene in tetrahydrofuran was slowly added. And after the dropwise addition is finished, stirring is continuously carried out until the reaction is complete.
Then 72 g of nonanal are added, after the reaction is complete the reaction is quenched with dilute hydrochloric acid and extracted with dichloromethane. Organic phase is combined, desolventized and purified by column chromatography. 68 g of compound 1 are obtained as a pale yellow liquid in 77% yield.
1H-NMR(300MHz,CDCl3)δ:0.88(t,3H),1.28-1.47(m,20H),2.06(m,2H),3.58(m,1H),4.93(dd,1H),5.00(dd,1H),5.80(m,1H)。
13C-NMR(100MHz,CDCl3)δ:14.11,22.72,25.23,25.75,29.07,29.37,29.69,29.82,31.96,33.82,37.35,37.57,71.83,114.34,138.92。
2. Synthesis of Compound 2a
10 ml of anhydrous tetrahydrofuran are mixed with 2.65 g of sodium hydride at room temperature, 10 g of compound 1 are then added, and 9.1 g of benzyl bromide are then added. After heating for 2 hours, the reaction was quenched with dilute hydrochloric acid, extracted with 100 ml of dichloromethane and concentrated to give 19.1 g of crude product, which was used directly in the next step.
1H-NMR(400MHz,CDCl3)δ:0.88(t,3H),1.27~1.56(m,20H),2.05(m,2H),3.36(m,1H),4.49(s,2H),4.92-5.02(m,2H),5.81(m,1H),7.25-7.36(m,5H)。
13C-NMR(100MHz,CDCl3)δ:14.11,22.72,25.23,25.75,29.07,29.37,29.69,29.82,31.96,33.82,37.35,37.57,71.83,114.34,138.92。
3. Synthesis of Compound 3a
Taking 17.1 g of the crude product of the compound 2a, adding 120 ml of dichloromethane and 12.0 g of m-chloroperoxybenzoic acid, and heating for reacting for 2 hours. The reaction solution was quenched with 10% aqueous sodium bicarbonate solution, separated, the aqueous phase was extracted once with 100 ml dichloromethane, the organic phase was concentrated and column chromatography was carried out to give 9.0 g of compound 3a with a total yield of 68% over the two steps.
1H-NMR(400MHz,CDCl3)δ:0.88(t,3H),1.27-1.56(m,20H),2.46(d,1H),2.74(t,1H),2.90(s,1H),3.37(m,1H),4.50(m,2H),7.27-7.34(m,5H)。
13C-NMR(100MHz,CDCl3)δ:13.79,22.04,24.52,24.65,25.63,28.63,28.96,29.17,31.24,31.86,33.10,38.90,39.32,39.52,39.73,45.92,51.33,69.70,127.01,127.25,127.94,129.15。
MS:332.5m/e,[M+H]+=332.2,[M+Na]+=355.2。
4. Synthesis of Compound 4a
72 ml of toluene and 3.0 g of sodium hydride are mixed at room temperature, and 18.3 g of triethyl phosphonoacetate are added dropwise. 9 g of compound 3a are added, the reaction is heated for 2 hours and quenched by the addition of acetic acid. Concentration followed by column chromatography purification gave 6.4g of compound 4a, 59% yield.
1H-NMR(400MHz,CDCl3)δ:0.58-0.61(m,1H),0.88(t,3H),1.08(m,1H),1.06-1.50(m,27H),3.28(m,1H),4.04(q,2H),4.42(s,2H),7.19-7.27(m,5H)。
5. Synthesis of Compound 5a
10.4 g of compound 4a were mixed with 146 ml of toluene and 20 ml of dichloromethane, cooled with liquid nitrogen, and 33.58 ml of DIBAL-H solution was added and the reaction was continued for 15 minutes. The reaction was quenched with 30 ml of methanol, 150 ml of ethyl acetate was added, and after concentration, column chromatography gave 6 g of compound 5a with a yield of 65.2%.
1H-NMR(400MHz,CDCl3)δ:0.73-0.78(m,1H),0.88(t,3H),0.91-0.93(m,1H),1.13-1.63(m,24H),3.36(m,1H),4.49(m,2H),7.25-7.51(m,5H),8.98(m,1H)。
13C-NMR(100MHz,CDCl3)δ:14.28,15.03,22.75,22.78,22.79,25.12,25.47,29.40,29.66,29.67,32.00,32.74,33.89,33.92,370.89,76.95,77.38,78.98,114.45,127.53,127.87,128.40,129.64,200.18。
MS:358.5m/e,[M+Na]+=381.4。
6. Synthesis of Compound 6a
64 g of methoxymethyltriphenylphosphonium chloride and 30 ml of tetrahydrofuran are mixed and then 351 ml of KHMDS solution are added dropwise. Then 22.5 g of compound 5a was added, the reaction was quenched with 7 ml of methanol after stirring for 1 hour, and after concentration, 15 g of compound 6a was isolated by column chromatography with a yield of 62%.
1H-NMR(400MHz,CDCl3)δ:0.27-0.41(m,2H),0.48-0.56(m,1H),0.79(t,3H),0.83-0.90(m,1H),1.14-1.49(m,22H),3.27(m,1H),3.39(s,2H),3.53(s,1H),4.41(m,2H),5.78(m,1H),6.25(d,1H),7.17-7.26(m,5H)。
13C-NMR(100MHz,CDCl3)δ:13.23,14.27,17.02,20.41,22.84,25.34,25.52,29.45,29.70,29.76,29.77,30.02,32.05,34.01,34.04,34.15,56.17,70.90,79.20,111.02,106.85,127.52,127.91,128.45,139.35,145.34。
7. Synthesis of Compound 7a
15 g of compound 6a are dissolved in 135 ml of acetone, and 120 ml of 6N hydrochloric acid are then added. After stirring for 2 hours, 300 ml of ethyl acetate was added, and after separation, drying and concentration, 12 g of compound 7a was obtained with a yield of 83%.
1H-NMR(400MHz,CDCl3)δ:0.23-0.31(m,2H),0.43-0.46(m,1H),0.59-0.62(m,1H),0.80(t,4H),1.18-1.52(m,22H),2.19(m,2H),3.27(m,1H),4.41(s,2H),7.27-7.27(m,5H),9.71(d,1H)。
3C-NMR(100MHz,CDCl3)δ:11.68,11.85,13.38,14.27,22.83,25.42,25.51,29.45,29.77,29.93,30.02,32.05,34.02,34.10,34.25,39.21,70.88,79.21,102.04,127.34,127.77,127.88,128.42,129.31,202.66。
MS:372.5m/e,[M+Na]+=395.3。
8. Synthesis of Compound 8a
9 g of compound 7a and 180 ml of dioxane were mixed, 6.7 g of potassium dihydrogen phosphate was added, an aqueous sodium chlorite solution (5.4 g dissolved in 13.5 ml of water) was added dropwise thereto, and after stirring at room temperature for 1 hour, 500 ml of dichloromethane and 80 ml of water were added, followed by liquid separation and concentration of the organic layer to obtain 9 g of compound 8a with a yield of 96%.
1H-NMR(400MHz,CDCl3)δ:0.26(m,2H),0.48(m,1H),0.70(d,1H),0.82(t,3H),1.19-1.46(m,22H),2.18(d,2H),3.29(m,1H),4.43(s,2H),7.19-7.27(m,5H)。
MS:388.5m/e,[M+Na]+=411.4,[M-H]=387.2。
9. Synthesis of Compound 9b
1 g of compound 8a is mixed with 5 ml of dichloromethane, 0.63 g of DMAP and 0.95 g of tert-butanol are added, ice water is cooled to about 10 ℃, and a solution of 0.638 g of DCC in 5 ml of dichloromethane is added dropwise. After stirring at room temperature for 4 hours, 5 ml of dichloromethane were added, filtered, concentrated and subjected to column chromatography to obtain 0.8g of compound 9 b.
1H-NMR(400MHz,CDCl3)δ:0.21(m,2H),0.44(m,1H),0.64(m,1H),0.81(t,3H),1.19-1.44(m,31H),2.03(m,2H),3.28(m,1H),4.42(s,2H),7.19-7.28(m,5H)。
10. Synthesis of Compound 10a
2.6 g of compound 9b and 18 ml of methanol are mixed, 3.9 g of 10% Pd/C is added, hydrogen is introduced for reaction for 4 hours, the mixture is filtered, and the filtrate is desolventized to obtain 1.4 g of light yellow compound 10a liquid, wherein the yield is 67.6%.
1H-NMR(400MHz,CDCl3)δ:0.21(m,2H),0.45(m,1H),0.66(m,1H),0.81(t,3H),1.21-1.41(m,31H),1.96-2.12(m,2H),3.52(m,1H)。
11. Synthesis of Compound of formula (Ib)
1.4 g of compound 10a and 10 ml of dichloromethane were mixed, 3.12 g of pyridine was added, 0.68 g of methanesulfonyl chloride was added dropwise, and the mixture was stirred at room temperature for 16 hours. After desolventization, column chromatography gave 1.2 g of compound of formula (Ib) in 70.5% yield.
1H-NMR(400MHz,CDCl3)δ:0.29(m,2H),0.52(m,1H),0.73(m,1H),0.88(t,3H),1.23-45(m,27H),1.64-1.72(m,4H),2.11(m,2H),2.99(s,3H),4.69(m,1H)。
MS:432.6m/e,[M+Na]+=455.3。
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art will understand that various changes, modifications and substitutions can be made without departing from the spirit and scope of the present invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims (28)

1. A process for the preparation of a compound of formula (I),
Figure FDA0003077295680000011
wherein R represents C1-6Alkyl radical, C1-6Haloalkyl, C2-6Alkenyl radical, C2-6Alkynyl, C3-7Cycloalkyl, 3-7 membered heterocyclyl, C6-10Aryl or 5-10 membered heteroaryl;
x is sulfonyl;
it was prepared using compound 7:
Figure FDA0003077295680000012
wherein Pg represents a protecting group;
the method comprises the step of subjecting compound 3 to Wadsworth-Emmons cyclopropanation reaction to obtain compound 4:
Figure FDA0003077295680000013
a step of reducing compound 4 to give compound 5:
Figure FDA0003077295680000014
a step of subjecting compound 5 to Wittig reaction, thereby obtaining compound 6:
Figure FDA0003077295680000015
step of hydrolyzing compound 6 to compound 7:
Figure FDA0003077295680000021
step of oxidizing compound 7 to compound 8:
Figure FDA0003077295680000022
esterification of compound 8 to give compound 9:
Figure FDA0003077295680000023
a step of deprotecting compound 9 to obtain compound 10:
Figure FDA0003077295680000024
2. the process according to claim 1, wherein Pg is a protecting group selected from benzyl, 4-methylbenzyl, 4-methoxybenzyl, tert-butyldimethylsilyl, triisopropylsilyl and triethylsilyl.
3. A process according to claim 2, wherein Pg is benzyl.
4. The process according to claim 1, wherein R is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, cyclopropyl or cyclopentyl;
x is selected from methylsulfonyl, p-toluenesulfonyl, trifluoromethanesulfonyl;
the Wadsworth-Emmons cyclopropanation reaction is carried out in the presence of an organic base.
5. The process according to claim 4, wherein R is tert-butyl, X is methylsulfonyl and the organic base is selected from LDA, potassium tert-butoxide, butyllithium, LiHMDS, NaHMDS or KHMDS.
6. The process according to claim 1, wherein R is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, cyclopropyl or cyclopentyl;
x is selected from methylsulfonyl, p-toluenesulfonyl, trifluoromethanesulfonyl;
the Wadsworth-Emmons cyclopropanation is carried out in the presence of sodium hydride or sodium amide.
7. A process according to claim 6, wherein the Wadsworth-Emmons cyclopropanation is carried out in the presence of sodium hydride.
8. The process according to claim 1, wherein the oxidation reaction is carried out using an oxidizing agent selected from the group consisting of: sodium chlorite, potassium permanganate, PCC or manganese dioxide.
9. The process according to claim 1, further comprising the step of sulfonylating compound 10 to provide a compound of formula (I):
Figure FDA0003077295680000031
10. the process according to claim 1, wherein the hydrolysis reaction is carried out under acidic conditions.
11. The process according to claim 10, wherein the hydrolysis reaction is carried out using an acid selected from the group consisting of: hydrochloric acid, perchloric acid, sulfuric acid, methanesulfonic acid, trifluoromethanesulfonic acid, or trifluoroacetic acid.
12. The process according to claim 1, wherein the Wittig reaction is carried out in the presence of an organic base.
13. The process according to claim 12, wherein the organic base is selected from LDA, potassium tert-butoxide, butyllithium, LiHMDS, NaHMDS or KHMDS.
14. The process according to claim 1, wherein the Wittig reaction is carried out in the presence of sodium hydride or sodium amide.
15. The process according to claim 14, wherein the Wittig reaction is carried out in the presence of sodium hydride.
16. The process according to claim 1, wherein the reduction reaction uses DIBAL-H to selectively reduce the ester to the aldehyde.
17. The process according to claim 1, wherein the reduction reaction comprises a two-step reaction of first reducing the ester completely to the alcohol and then oxidizing the alcohol to the aldehyde.
18. The method of claim 17, wherein the first reaction step uses NaBH4Borane-tetrahydrofuran complex, lithium aluminum hydride, DIBAL-H,Or red aluminum and the second reaction is carried out using activated manganese dioxide, PCC or dessimutane reagents.
19. The method according to claim 1, further comprising the step of epoxidizing the double bond in compound 2 to give compound 3:
Figure FDA0003077295680000032
20. the process according to claim 19, wherein the epoxidation is carried out using an agent selected from the group consisting of: mCPBA, hydrogen peroxide, peracetic acid, t-butanol peroxide, or cumene peroxide.
21. The method of claim 20, wherein the epoxidation is performed using mCPBA.
22. The process according to claim 1, further comprising the step of protecting the hydroxyl group of compound 1 with a protecting group Pg to give compound 2:
Figure FDA0003077295680000041
23. the method according to claim 1, further comprising the step of subjecting the starting materials aldehyde and halide to a nucleophilic addition reaction of a metal organic reagent and aldehyde to obtain compound 1:
Figure FDA0003077295680000042
wherein R is1Is an aldehyde group, R2Is halogen; or R1Is halogen, R2Is an aldehyde group.
24. The method according to claim 23, wherein the halogen is Cl or Br; the reaction is carried out in tetrahydrofuran, 2-methyltetrahydrofuran or diethyl ether organic solvent with magnesium, indium, zinc or lithium as metal.
25. The process according to claim 24, wherein the reaction is carried out with magnesium as metal in tetrahydrofuran.
26. A method according to any one of claims 23 to 25, comprising the steps of:
Figure FDA0003077295680000043
27. the method according to claim 1, comprising the steps of:
Figure FDA0003077295680000051
28. the method according to claim 27, comprising the steps of:
Figure FDA0003077295680000052
CN201710250117.9A 2017-04-17 2017-04-17 Novel process route for modifying fatty acid type PET reagent precursor Active CN108727229B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710250117.9A CN108727229B (en) 2017-04-17 2017-04-17 Novel process route for modifying fatty acid type PET reagent precursor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710250117.9A CN108727229B (en) 2017-04-17 2017-04-17 Novel process route for modifying fatty acid type PET reagent precursor

Publications (2)

Publication Number Publication Date
CN108727229A CN108727229A (en) 2018-11-02
CN108727229B true CN108727229B (en) 2021-07-02

Family

ID=63924633

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710250117.9A Active CN108727229B (en) 2017-04-17 2017-04-17 Novel process route for modifying fatty acid type PET reagent precursor

Country Status (1)

Country Link
CN (1) CN108727229B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114700006B (en) * 2022-06-07 2023-03-24 北京先通国际医药科技股份有限公司 Production equipment of liquid composition and preparation method and application thereof
CN116199658A (en) * 2022-07-22 2023-06-02 北京先通国际医药科技股份有限公司 Synthesis method and application of modified long-chain fatty acid type PET reagent precursor
CN115181013B (en) * 2022-07-22 2023-08-08 北京先通国际医药科技股份有限公司 Preparation method and application of key intermediate of modified fatty acid type PET reagent precursor
CN116041169A (en) * 2022-07-29 2023-05-02 北京先通国际医药科技股份有限公司 Process route for synthesizing key intermediate of modified fatty acid type PET reagent precursor and application thereof
CN115141087B (en) * 2022-09-06 2023-03-24 北京先通国际医药科技股份有限公司 Synthesis method and application of isomers of PET precursor key intermediate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004093650A2 (en) * 2003-04-17 2004-11-04 The General Hospital Corporation Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid
US10407378B2 (en) * 2014-04-21 2019-09-10 Takasago International Corporation Compound, and flavor and/or fragrance composition containing said compound
JP2017043615A (en) * 2015-08-27 2017-03-02 塩野義製薬株式会社 Cyclopropane amino acid unit that improves membrane permeability and/or metabolic stability of cyclic peptide

Also Published As

Publication number Publication date
CN108727229A (en) 2018-11-02

Similar Documents

Publication Publication Date Title
CN108727229B (en) Novel process route for modifying fatty acid type PET reagent precursor
CN118515685A (en) Synthesis of halichondrin
Pasto et al. Transfer Reactions Involving Boron. IX. Mechanism of Product Formation in the Hydroboration of Vinyl Halides1, 2
CN112125803B (en) Preparation of homoallylic alcohol compound, synthetic method and application thereof
CN111328332B (en) Process for the preparation of bile acids
GB673451A (en) Process for the production of organic phosphines
DE3783694T2 (en) METHOD FOR PRODUCING MYOINOSITOL COMBINATIONS.
ES2691077T3 (en) Process for the preparation of ingenol-3-angelato from 20-desoxi-ingenol
CN115959978B (en) Synthesis method and application of modified long-chain fatty acid type PET reagent precursor
Pal et al. Single-pot conversion of an acid to the corresponding 4-chlorobutyl ester
CN116041169A (en) Process route for synthesizing key intermediate of modified fatty acid type PET reagent precursor and application thereof
Reddy et al. Stereoselective Total Synthesis of the Natural Oxylipin (6R, 7E, 9R, 10S)-6, 9, 10-Trihydroxyoctadec-7-enoic Acid1
JPS5949236B2 (en) 2-Hydroxyethylphosphine
SU393264A1 (en) METHOD FOR OBTAINING TETRAGALOIDMETHANE ADDUDES WITH ACRYLIC COMPOUNDS
JPWO2003070684A1 (en) Method for producing chain oligolactic acid ester
CN115181013B (en) Preparation method and application of key intermediate of modified fatty acid type PET reagent precursor
JPS637170B2 (en)
SU891632A1 (en) Method of producing beta-acyloxyketone
KR101088266B1 (en) Carotinoid intermediate compound, preparing method thereof, and method for preparing carotinoid compound, astaxanthin and astacene using the same
SU1594162A1 (en) Method of producing 1-substituted cyclopropanes
US4005109A (en) Preparation of prostaglandin intermediates
CN116217356A (en) Synthesis method and application of isomer of PET precursor key intermediate
SU1049469A1 (en) Process for preparing capric acid
Kelly General preparation of arylacetic acid precursors. A further example of the iron tricarbonyl group as an agent for lateral control and activation in reactivity of cyclohexa-1, 3-dienes
US20040147789A1 (en) Allyl esters substituted by a difluoromethylene group, their process of synthesis and their use, and a process for functionalizing a double bond

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant